Dupixent (dupilumab) prior authorization criteria for chronic spontaneous urticaria (CSU)
Customize your policy alerts
Sign up for all Mississippi Division of Medicaid policy alerts
Know when Mississippi Division of Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for Dupixent (dupilumab) when prescribed for chronic spontaneous urticaria (CSU) for Mississippi Division of Medicaid members; defines requirements for initial and reauthorization approvals and documentation expectations.
No material clinical or coverage changes in this revision.
Coverage Criteria for Dupixent (dupilumab) — Chronic Spontaneous Urticaria
inv-01: Initial Authorization
Initial authorization (issued for 6 months). Approval requires ALL of the following:
chunk 2
chunk 2
chunk 2
chunk 3
chunk 3
chunk 3
inv-02: Reauthorization
Reauthorization (issued for 12 months). Approval requires ALL of the following:
chunk 4
chunk 4
chunk 4
The policy specifies that Dupixent (dupilumab) is indicated only for chronic spontaneous urticaria (CSU) and explicitly states it is not indicated for other forms of urticaria (non‑CSU presentations). Prior authorization and coverage criteria in this policy apply solely to CSU and do not support use for alternative urticaria diagnoses.
Provider Requirements, Documentation, and Denial Triggers
Prior authorization required; initial 6 months, reauth 12 months
Prior authorization is required for Dupixent (dupilumab) when prescribed for chronic spontaneous urticaria (CSU). Initial approvals are issued for 6 months; reauthorization approvals are issued for 12 months when reauthorization criteria are met. Include the Universal PA Form and supporting clinical documentation with the request.
Required H1 antihistamine trials (2‑week trials or documented intolerance)
Document that the patient remained symptomatic despite appropriate H1 antihistamine therapy. Approval requires either: (a) at least a 2‑week trial of, or documented contraindication/intolerance to, two H1 antihistamines; OR (b) at least a 2‑week trial of, or documented contraindication/intolerance to, both agents in a combination regimen consisting of a second‑generation H1 antihistamine plus one additional agent (a different second‑generation H1, a first‑generation H1, an H2 antihistamine, or a leukotriene modifier).
- Examples of second‑generation H1 antihistamines: cetirizine, loratadine, desloratadine, levocetirizine
- Examples of first‑generation H1 antihistamines: chlorpheniramine, diphenhydramine, hydroxyzine
- Examples of H2 antihistamines: famotidine, cimetidine, nizatidine
- Example leukotriene modifier: montelukast
Required documentation with PA submission
Submit the Universal PA Form and any supporting clinical documentation demonstrating the diagnosis of chronic spontaneous urticaria, age per FDA labeling, prior antihistamine therapy trials or documented contraindications/intolerances, specialist involvement or consultation, prescribed dosing, and clinical response when applicable.
- Evidence of patient age consistent with FDA label (≥ 2 years)
- Documentation of prior antihistamine trials (duration and agents) or reason trials were not completed
- Notes confirming prescription by or consultation with an allergist, immunologist, or dermatologist
- Current Dupixent dosing (initial and maintenance) and any response to therapy
Denial triggers if criteria or documentation are incomplete
PA may be denied if required criteria are not met. Common triggers include missing or inconsistent documentation of age within the FDA label, absence of a CSU diagnosis, insufficient antihistamine trials or lack of documented intolerance/contraindication, no specialist involvement, concurrent use of another biologic, or dosing that exceeds policy limits.
- Age not documented or outside FDA‑recommended range
- No documented diagnosis of chronic spontaneous urticaria
- Insufficient trial duration or number of H1 antihistamines without documented intolerance/contraindication
- Prescriber not an allergist, immunologist, or dermatologist and no documented consultation
- Concomitant biologic therapy (e.g., tralokinumab, omalizumab, mepolizumab, reslizumab, benralizumab)
- Prescribed dose exceeds initial 600 mg then 300 mg q2w (initial) or maintenance >300 mg q2w for reauthorization
Key Definitions
Background on Dupixent (dupilumab)
Dupixent (dupilumab) is an interleukin‑4 receptor alpha antagonist approved for the treatment of patients aged 2 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine therapy. The policy frames Dupixent’s mechanism and indication succinctly to guide prior authorization and documentation requirements for CSU treatment.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.